Literature DB >> 19432564

The management of epilepsy in pregnancy.

S P Walker1, M Permezel, S F Berkovic.   

Abstract

While most women with epilepsy can expect a normal pregnancy outcome, epilepsy remains a significant contributor to both maternal and perinatal morbidity. Pre-pregnancy planning must address reliable contraception and optimisation of antiepileptic drug (AED) regimens to minimise teratogenic risk while maintaining seizure control. The most recent data from the AED registries regarding malformations is presented in this review, as is the limited data on the newer AEDs and studies linking neurocognitive outcomes to AED exposure. During pregnancy, important considerations include; therapeutic drug monitoring, surveillance for obstetric complications and vigilance for seizures during the intrapartum and postpartum period.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19432564     DOI: 10.1111/j.1471-0528.2009.02141.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  4 in total

Review 1.  Treatment and care of women with epilepsy before, during, and after pregnancy: a practical guide.

Authors:  Bruna Nucera; Francesco Brigo; Eugen Trinka; Gudrun Kalss
Journal:  Ther Adv Neurol Disord       Date:  2022-06-11       Impact factor: 6.430

2.  The management of epilepsy in pregnancy at the Whittington Hospital: a retrospective audit 2004-2006 and 2007-2010.

Authors:  Rebecca Allen; Liliana Grosu; Ishita Das; Amma Kyei-Mensah
Journal:  Obstet Med       Date:  2013-05-03

3.  Use of topiramate in pregnancy and risk of oral clefts.

Authors:  Andrea V Margulis; Allen A Mitchell; Suzanne M Gilboa; Martha M Werler; Murray A Mittleman; Robert J Glynn; Sonia Hernandez-Diaz
Journal:  Am J Obstet Gynecol       Date:  2012-07-16       Impact factor: 8.661

4.  Obstetric and birth outcomes in pregnant women with epilepsy: A hospital-based study.

Authors:  Noor Haslina Othman; Ab Fatah Ab Rahman
Journal:  Ann Indian Acad Neurol       Date:  2013-10       Impact factor: 1.383

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.